Needham & Company Reiterates Buy Rating, $20 Price Target on CorMedix (CRMD) Ahead of DefenCath's 3Q22 PDUFA
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $20.00 price target on CorMedix (NASDAQ: CRMD), as the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
